Irumed

Lisinopril, the active ingredient in Irumed, is an ACE inhibitor presented as an oral tablet for oral use. It lowers high blood pressure and supports treatment of heart failure, post‑myocardial infarction and diabetic kidney disease in adult patients.

GNH USA supplies Irumed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. With a robust distribution network, GNH USA ensures timely delivery and reliable supply chain management across European and international markets.

Lisinopril is used to manage conditions within the renin‑angiotensin system that affect blood pressure and cardiac function.

Hypertension: reduces systolic and diastolic blood pressure, decreasing risk of stroke and cardiovascular events. Heart failure: improves symptoms and lowers mortality by decreasing cardiac workload. Post‑myocardial infarction: lowers the chance of subsequent heart failure and improves survival. Diabetic nephropathy: slows progression of kidney damage by lowering intraglomerular pressure.

Lisinopril may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Cough: dry, persistent cough. - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue. - Nausea. - Mild hyperkalaemia.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, potentially compromising the airway. - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden decline in renal function. - Hepatotoxicity: significant liver enzyme elevations. - Neutropenia or leukopenia: low white‑blood‑cell counts. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Lisinopril, clinicians should evaluate several safety considerations.

Renal function: assess baseline creatinine and eGFR; adjust if impaired. Serum potassium: monitor for hyperkalaemia, especially with potassium‑sparing diuretics. Pregnancy: contraindicated in the second and third trimesters; avoid use in pregnant women. Angioedema history: avoid in patients with prior ACE‑inhibitor‑induced angioedema. Drug interactions: review concomitant medicines that affect potassium or renal function. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Lisinopril can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use in diabetes increases risk of renal impairment, hyperkalaemia, and hypotension. - Sacubitril/valsartan: concurrent use may cause excessive angiotensin blockade and hypotension. - Potassium‑sparing diuretics (e.g., spironolactone): risk of severe hyperkalaemia. - NSAIDs (high dose): may reduce antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Diuretics (loop or thiazide): may enhance hypotensive effect; monitor blood pressure. - Lithium: Lisinopril can increase lithium levels; monitor for toxicity. - Antidiabetic drugs (insulin, sulfonylureas): may need dose adjustment due to improved glycaemic control. - Rifampin: may decrease Lisinopril plasma concentration.